Joseph W.  LaPlume net worth and biography

Joseph LaPlume Biography and Net Worth

Joseph W. LaPlume joined Charles River in 2005, was named the Company’s Corporate Senior Vice President, Corporate Development in 2014, and promoted to Corporate Executive Vice President, Corporate Development & Strategy in 2019. Mr. LaPlume is responsible for strategic acquisitions and expanding the Company’s portfolio and geographic footprint. Mr. LaPlume was promoted from Corporate Vice President, Corporate Development, a position that he held from 2011, and has been instrumental in enhancing the Company’s growth profile through several acquisitions and multiple licensing transactions. Mr. LaPlume was formerly Deputy General Counsel at Charles River, and began his career at Charles River as a corporate lawyer in 2005. Prior to joining Charles River, Mr. LaPlume had extensive experience in both corporate law and mergers and acquisitions at Mintz Levin, Goulston & Storrs, and GTECH Corporation.

Mr. LaPlume received M.B.A. and J.D. degrees from Boston University, and Bachelor’s degree from Trinity College.

What is Joseph W. LaPlume's net worth?

The estimated net worth of Joseph W. LaPlume is at least $4.37 million as of May 10th, 2024. Mr. LaPlume owns 23,276 shares of Charles River Laboratories International stock worth more than $4,373,560 as of November 21st. This net worth estimate does not reflect any other assets that Mr. LaPlume may own. Additionally, Mr. LaPlume receives an annual salary of $928,360.00 as EVP at Charles River Laboratories International. Learn More about Joseph W. LaPlume's net worth.

How old is Joseph W. LaPlume?

Mr. LaPlume is currently 50 years old. There are 5 older executives and no younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International is Mr. James C. Foster J.D., CEO, President & Chairman, who is 73 years old. Learn More on Joseph W. LaPlume's age.

What is Joseph W. LaPlume's salary?

As the EVP of Charles River Laboratories International, Inc., Mr. LaPlume earns $928,360.00 per year. There are 4 executives that earn more than Mr. LaPlume. The highest earning executive at Charles River Laboratories International is Mr. James C. Foster J.D., CEO, President & Chairman, who commands a salary of $2,660,000.00 per year. Learn More on Joseph W. LaPlume's salary.

How do I contact Joseph W. LaPlume?

The corporate mailing address for Mr. LaPlume and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Joseph W. LaPlume's contact information.

Has Joseph W. LaPlume been buying or selling shares of Charles River Laboratories International?

Joseph W. LaPlume has not been actively trading shares of Charles River Laboratories International during the last quarter. Most recently, Joseph W. Laplume sold 1,304 shares of the business's stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a transaction totalling $295,968.88. Following the completion of the sale, the executive vice president now directly owns 23,276 shares of the company's stock, valued at $5,282,953.72. Learn More on Joseph W. LaPlume's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, insiders at the medical research company sold shares 5 times. They sold a total of 22,857 shares worth more than $5,420,562.80. The most recent insider tranaction occured on November, 7th when Director Richard F Wallman sold 6,621 shares worth more than $1,430,930.52. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 11/7/2024.

Joseph W. LaPlume Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2024Sell1,304$226.97$295,968.8823,276View SEC Filing Icon  
8/10/2023Sell700$216.52$151,564.0024,983View SEC Filing Icon  
5/15/2023Sell345$190.39$65,684.5524,026View SEC Filing Icon  
12/1/2022Sell6,409$224.25$1,437,218.2520,232View SEC Filing Icon  
11/4/2022Sell534$216.36$115,536.2420,232View SEC Filing Icon  
8/5/2022Sell200$226.13$45,226.0020,766View SEC Filing Icon  
2/22/2022Sell396$290.83$115,168.68View SEC Filing Icon  
2/18/2022Sell1,143$291.80$333,527.40View SEC Filing Icon  
8/6/2021Sell3,700$402.21$1,488,177.00View SEC Filing Icon  
2/25/2021Sell8,735$281.70$2,460,649.50
11/4/2020Sell6,739$250.28$1,686,636.92
3/8/2019Sell5,522$137.61$759,882.4216,325View SEC Filing Icon  
See Full Table

Joseph W. LaPlume Buying and Selling Activity at Charles River Laboratories International

This chart shows Joseph W Laplume's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $187.90
Low: $183.55
High: $188.32

50 Day Range

MA: $195.05
Low: $178.58
High: $220.69

2 Week Range

Now: $187.90
Low: $176.48
High: $275.00

Volume

632,084 shs

Average Volume

889,008 shs

Market Capitalization

$9.61 billion

P/E Ratio

23.52

Dividend Yield

N/A

Beta

1.38